Limitations, agreements, and source contact

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment · Source last updated 2026-02-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details

Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.

pi Sponsor Employee

false

restriction Type

OTHER

restrictive Agreement

true

limitations And Caveats

description

ASTCT: American Society for Transplantation and Cellular Therapy. CTCAE: Common Terminology Criteria for Adverse Events. g/dl: Gram/deciliter mg: Milligram BM: Bone marrow Cm: Centimeter SPD: Sum of the products of diameters mcl: Microliter

point Of Contact

email

ClinicalTrials.gov_Inquiries@pfizer.com

organization

Pfizer Inc.

phone

1-800-718-1021

title

Pfizer ClinicalTrials.gov Call Center

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice